PMID- 23805377 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211021 IS - 2048-8505 (Print) IS - 2048-8513 (Electronic) IS - 2048-8505 (Linking) VI - 6 IP - 2 DP - 2013 Apr TI - Focal segmental glomerulosclerosis in association with neurofibromatosis type 1: a case report and proposed molecular pathways. PG - 208-210 AB - A 42-year-old Caucasian female with history of neurofibromatosis type 1 presented with nephrotic range proteinuria and focal segmental glomerulosclerosis (FSGS). On final dose of lisinopril 20 mg/day, protein-creatinine ratio declined to 0.33 within 10 months. We propose the hypothesis that development of FSGS in NF1 may be mediated by activation of mitogen-activated protein kinase (MAPK) and mammalian target of rapamycin (mTOR) signaling pathways secondary to up-regulation of ras proteins due to deficient neurofibromin. Since mTOR signaling pathway is partially mediated through angiotensin-II activation, angiotensin-converting enzyme (ACE) inhibition may serve as an effective initial treatment beyond anti-proteinuric properties of ACE-inhibitors. FAU - Afshinnia, Farsad AU - Afshinnia F AD - Division of Nephrology, Department of Internal Medicine , University of Michigan , Ann Arbor, MI , USA. FAU - Vega-Warner, Virginia AU - Vega-Warner V FAU - Killen, Paul AU - Killen P LA - eng GR - T32 DK007378/DK/NIDDK NIH HHS/United States PT - Journal Article PL - England TA - Clin Kidney J JT - Clinical kidney journal JID - 101579321 PMC - PMC3693487 OTO - NOTNLM OT - MAPK OT - focal segmental glomerulosclerosis OT - mTOR OT - neurofibromatosis EDAT- 2013/06/28 06:00 MHDA- 2013/06/28 06:01 PMCR- 2013/04/01 CRDT- 2013/06/28 06:00 PHST- 2012/11/18 00:00 [received] PHST- 2013/01/08 00:00 [accepted] PHST- 2013/06/28 06:00 [entrez] PHST- 2013/06/28 06:00 [pubmed] PHST- 2013/06/28 06:01 [medline] PHST- 2013/04/01 00:00 [pmc-release] AID - sft010 [pii] AID - 10.1093/ckj/sft010 [doi] PST - ppublish SO - Clin Kidney J. 2013 Apr;6(2):208-210. doi: 10.1093/ckj/sft010.